Shionogi & Co logo

4507 - Shionogi & Co News Story

¥6234 32.0  0.5%

Last Trade - 14/08/20

Sector
Healthcare
Size
Large Cap
Market Cap £13.56bn
Enterprise Value £11.07bn
Revenue £2.23bn
Position in Universe 68th / 3863

BRIEF-GSK Says Long-Acting Injectable Cabotegravir 65% More Effective Than Truvada

Tue 7th July, 2020 2:00pm
July 7 (Reuters) - 
    * VIIV HEALTHCARE - EFFICACY OF CABOTEGRAVIR COMPARED TO DAILY ORAL
EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE 200 MG AND 300 MG (FTC/TDF) TABLETS
    * VIIV HEALTHCARE - LONG-ACTING CABOTEGRAVIR, FTC/TDF TABLETS BOTH WELL
TOLERATED
THROUGHOUT STUDY
    * GSK'S VIIV - DATA SHOWS LONG-ACTING INJECTABLE CABOTEGRAVIR GIVEN EVERY
TWO
MONTHS 65% MORE EFFECTIVE VERSUS DAILY PILLS IN STOPPING HIV ACQUISITION
    * VIIV - MOST PARTICIPANTS IN CABOTEGRAVIR GROUP (80%) REPORTED PAIN OR
TENDERNESS
AT INJECTION SITE VERSUS 31% OF THOSE IN FTC/TDF ARM, WHO GOT PLACEBO
    * VIIV HEALTHCARE - PLANS TO USE DATA FROM HPTN 083 FOR FUTURE REGULATORY
SUBMISSIONS
    * VIIV HEALTHCARE - MOST ADVERSE EVENTS OF STUDY MILD OR MODERATE IN NATURE
AND
BALANCED BETWEEN BOTH TREATMENT ARMS
    * VIIV - STUDY CONDUCTED IN MEN WHO HAVE SEX WITH MEN, TRANSGENDER WOMEN WHO
HAVE
SEX WITH MEN; FURTHER STUDY BEING CONDUCTED IN SEXUALLY ACTIVE WOMEN

Source text for Eikon:  ID:nNDL8fDvX2 
Further company coverage:  GSK.L 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.